Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence?
Delveinsight
SEPTEMBER 8, 2021
Hydroxychloroquine and BENLYSTA are the FDA-approved therapies for SLE treatment. With the approval of these therapies, the outlook for SLE patients improved from a 4-year survival rate of ~50% in 1950 to a 15-year survival rate of ~85% by 2013. Currently, the SLE therapeutics market is revolving around only one drug i.e
Let's personalize your content